MMJ’s Canadian cannabis investment Weed Me attracts new capital
Published 10-MAR-2020 13:09 P.M.
|
2 minute read
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
MMJ Group Holdings Limited (ASX:MMJ), a company that specialises in managing a portfolio of investments along the cannabis value-chain, advised on Tuesday that the privately owned Canadian cannabis business, Weed Me Inc. had completed a C$2.5 million capital raising.
MMJ Group has been an investor in Weed Me since December 2017 and it represents one of the largest investments within the company’s cannabis and hemp portfolio.
MMJ has a comprehensive and diversified interest in the cannabis and hemp industry as it owns a portfolio of minority investments and aims to invest across the full range of emerging cannabis-related sectors including healthcare, technology, infrastructure, logistics, processing, cultivation, equipment and retail.
As we will discuss later, the value of the company’s net tangible assets represents a 150% premium to the group’s current trading range, suggesting there is scope for significant share price upside, particularly if positive sentiment towards the sector returns.
Established in 2016, Weed Me is a licensed producer of cannabis with indoor growing facilities in Ontario, and it holds cultivation, processing and sales licenses under the Cannabis Act from Health Canada.
MMJ non-executive chairman Peter Wall highlighted the significance of Weed Me’s ability to attract funding in the face of negative sentiment towards the sector over the last 12 months.
Wall said, “We congratulate the management of Weed Me in securing funding in challenging market conditions and believe that it reflects the quality of its business plan and its substantial cultivation assets.“
‘’We are committed to working closely with Weed Me to deliver superior returns.”
MMJ not afraid to lock in gains
MMJ has a demonstrated track record of making astute investments in the industry, as well as timing the realisation of gains to the advantage of shareholders.
For example, MMJ saw MediPharm LABS’s (LABS) potential to establish itself as a leader in cannabis oils extraction, investing C$5 million in shares and warrants.
As the company experienced substantial share price growth throughout 2018, MMJ realised a return of six times capital invested.
The company’s success in achieving these results is reflected in its net tangible assets (NTA) per share as at December 31, 2019.
The NTA of 23.5 cents implies upside of 150% to this morning’s opening share price of 9.5 cents.
As the following table indicates, MMJ’s targeting of Canada appears to be a right time/right place decision.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
